55.5K
Downloads
174
Episodes
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions. Each episode brings conversations with information and experiences from expert professionals and people living with these challenging disorders.
Episodes
Monday Feb 01, 2021
Monday Feb 01, 2021
In today's podcast, we highlight a new company dedicated to the rare endocrine disease world. Tiburio Therapeutics is working on two exciting compounds for the treatment of Non-functioning Pituitary Adenomas and rare endocrine disorders.
Last week Dr. Blevins and I caught up with Abe Ceesay, Tiburio CEO and Nerissa Kreher M.D., Chief Medical Officer, both highly experienced professionals in the rare endocrine space. We had a fascinating talk about their plans in this area of extensive need for patients. Here’s our talk.
Monday Feb 01, 2021
S6E4: 4. "The journey to a new drug": understanding molecules and receptors
Monday Feb 01, 2021
Monday Feb 01, 2021
This podcast, the fourth in our drug development series “the journey to a new drug,” brings you my conversation with Dr. Stephen Betz, cofounder at Crinetics Pharmaceutical. Our discussion spotlights new drugs for acromegaly, Cushing’s, and pediatric hyperinsulinism, currently under development at Crinetics. It includes a fascinating talk on molecules and how they work with cell receptors to eventually provide a launching pad for new drugs.
We hope this podcast will serve up a better understanding of the many steps required to find and bring new medications and therapies to patients.
Monday Feb 01, 2021
S6E3: 3. Giving patients a place at the table
Monday Feb 01, 2021
Monday Feb 01, 2021
The third podcast in our series on drug development touches on the effort that industry is making to partner with patients to understand needs, preferences, and attitudes, and to develop insights that would result in better drugs and therapeutic experiences. In our conversation with Stephanie Kallay, Crinetics Director of Patient Advocacy, we discuss their effort to, as Stephanie put it, give the patient a place at the table. We talked about listening to the voice of the patient, the opportunities and challenges of engaging patients and the efforts that the industry is making to include their perspectives in everything they do.
Monday Feb 01, 2021
S6E2: 2. The business and commercial considerations
Monday Feb 01, 2021
Monday Feb 01, 2021
The second podcast in our continuing series on drug development focuses on the commercial and business aspects of getting a growing company ready for a new drug. Today we talk with Gina Ford, Crinetics’ Vice president of Corporate Strategy and Commercial Planning, about the challenges and opportunities as these new potential medications move through the development pipeline.
Monday Feb 01, 2021
Monday Feb 01, 2021
This is the first in a series of 6 podcasts on the ins and outs of drug development. In it, we discuss the journey that a promising molecule takes to develop into a life-saving medication and the people that steer that rigorous work. How does a company go from a molecule to the actual medication? What are the steps? Who is involved? What are the processes and barriers? And what does that process look like in real-time? Thanks to a kind invitation from Dr. Scott Struthers, chairman of Crinetics Pharmaceutical and his team, PWN readers and listeners will get an unfettered look at a young company's efforts to develop new drugs to solve unmet needs in acromegaly, Cushing's and rare neuroendocrine disease. Don’t miss it!
Monday Feb 01, 2021
Monday Feb 01, 2021
Today's podcast discusses HCG and its use with men with hypopituitarism and infertility. Dr. Blevins focuses his discussion on many of the relevant subjects related to hypogonadism (where the body does not produce enough testosterone), especially as it relates to hypopituitarism, a condition in which the pituitary gland does not produce one or more of its hormones or not enough of them to function normally
Monday Feb 01, 2021
S5E14: A fascinating chat between a patient and her doctor
Monday Feb 01, 2021
Monday Feb 01, 2021
Don't miss today's podcasts. Sometimes it is through these genuine, unscripted chats that we get insight into what it is like to deal with chronic pituitary disease, in this case, acromegaly. This podcast is no exception. In it, Dr. Blevins and his patient Monica talk about it and deliver a fascinating perspective
Monday Feb 01, 2021
S5E13: Silent Pituitary Adenomas
Monday Feb 01, 2021
Monday Feb 01, 2021
Our podcast today is on silent pituitary adenomas. This is a fascinating look into these tumors that are thought not to secrete hormones. In the podcast Dr. Blevins discusses the complexities and challenges when dealing with these specific adenomas. The podcast also mentions a recent paper on the subject published in the Journal of Clinical Endocrinology and Metabolism. Click here to read more about the abstract.
Monday Feb 01, 2021
S5E12: Pegvisomant, glucose metabolism, and acromegaly
Monday Feb 01, 2021
Monday Feb 01, 2021
In this podcasts, we discuss an important recent meta-analysis study from the University of Rome on the relationship between pegvisomant, a drug used for the treatment of acromegaly, and glucose metabolism. Dr. Blevins also dives into a fascinating discussion about meta-analysis studies, their advantages, and limitations and, importantly, the need to be very cautious when reading the results. Like in any search, there is excellent information out there, but there is also copious amounts of trash.
Monday Feb 01, 2021
S5E11: Why do adenomas recur?
Monday Feb 01, 2021
Monday Feb 01, 2021
Today's podcast is about silent Corticotropic adenomas and the recurrence rate of these tumors vs. all pituitary adenomas. Dr. Blevins weighs into a recent paper as well as current research to discuss why adenomas recur and importantly, why long term follow-up is essential and must be continued.